Molecular basis of multistep hepatocarcinogenesis: Genetic and epigenetic events

Scandinavian Journal of Gastroenterology

Volumn 34, Issue 8, 1999, Pages 737-742

  Hui, Ai Min ^a   Makuuchi, Masatoshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

CANCER GRADING; CANCER SUSCEPTIBILITY; CARCINOMA IN SITU; CELL CYCLE G1 PHASE; CHRONIC LIVER DISEASE; DISEASE COURSE; DNA METHYLATION; GENE ACTIVATION; GENE MUTATION; HEPATITIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; LIVER CARCINOGENESIS; LIVER CIRRHOSIS; MALIGNANT TRANSFORMATION; MOLECULAR MODEL; ONCOGENE; PRIORITY JOURNAL; REVIEW;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; DISEASE PROGRESSION; DNA METHYLATION; G1 PHASE; GENES, TUMOR SUPPRESSOR; HEPATITIS, CHRONIC; HUMANS; LIVER NEOPLASMS; MUTATION; ONCOGENES; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032857415     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655299750025642     Document Type: Review

References (65)

1. 1. Kim C-M, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991;351:317-20.
2. 2. Sakamoto M, Hirohashi S, Shimosato Y. Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol 1991;22:172-8.
3. 3. Hirohashi S, Sakamoto M. Hepatocellular carcinoma in the early stage, In: Tobe T, Kameda H, Okudaira M, Ohto M, Endo Y, Mito M, et al., editors. Primary liver cancer in Japan, Tokyo: Springer-Verlag; 1992. p. 25-30.
4. 4. Tsuda H, Hirohashi S, Shimusato Y, Terada M, Hasegawa H. Clonal origin of atypical adenomatous hyperplasia of the liver and clonal identity with hepatocellular carcinoma. Gastroenterology 1988;95:1664-6.
5. 5. Kanai T, Hirohashi S, Upton MP, Noguchi M, Kishi K, Makuuchi M, et al. Pathology of small hepatocellular carcinoma: a proposal for a new gross classification. Cancer 1987;60: 810-9.
6. 6. Edmondson AH, Steiner PE. Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies. Cancer 1954;7: 462-503.
7. 7. Sakamoto M, Hirohashi S, Tsuda H, Shimosato Y, Makuuchi M, Husoda Y. Multicentric independent development of hepatocellular carcinoma revealed by analysis of hepatitis B virus integration pattern. Am J Surg Pathol 1989;13:1064-7.
8. 8. Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Okazaki S, Takayasu K, et al. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 1990;336: 1150-3.
9. 9. Robinson WS. Molecular events in the pathogenesis of hepaDNAvirus-associated hepatocellular carcinoma. Annu Rev Med 1994;45:297-323.
10. 10. Tsuda H, Hirohashi S, Shimosato Y, Ino Y, Yoshida T, Terada M. Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma. Jpn J Cancer Res 1989;80:196-9.
11. 11. Boix L, Rosa JL, Ventura F, Castells A, Bruix J, Rodes J, et al. c-met mRNA overexpression in human hepatocellular carcinoma. Hepatology 1994;19:88-91.
12. 12. Hollstein M, Sidranksky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
13. 13. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-6.
14. 14. Murakami Y, Hayashi K, Hirohashi S, Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res 1991;51:5520-5.
15. 15. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 1992;52:6358-64.
16. 16. Oda T, Tsuda H, Sakamoto M, Hirohashi S. Different mutations of the p53 gene in nodule-in-nodule hepatocellular carcinoma as a evidence for multistage progression. Cancer Lett 1994;83: 197-200.
17. 17. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991;350:427-8.
18. 18. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutation of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991;350:429-31.
19. 19. Zhang X, Xu HJ, Murakami Y, Sachse R, Yashima K, Hirohashi S, et al. Deletions of chromosome 13q, mutations in retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 1994;54:4177-82.
20. 20. Zhang W, Hirohashi S, Tsuda H, Shimosato Y, Yokota J, Terada M, et al. Frequent loss of heterozygosity on chromosomes 16 and 4 in human hepatocellular carcinoma. Jpn J Cancer Res 1990;81:108-11.
21. 21. Tsuda H, Zhang W, Shimosato Y, Yokota J, Terada M, Sugimura T, et al. Allele loss on chromosome 16 associated with progression of human hepatocellular carcinoma. Proc Natl Acad Sci USA 1990;87:6791-4.
22. 22. Simon D, Knowles BB, Weith A. Abnormalities of chromosome 1 and loss of heterozygosity on 1p in primary hepatomas. Oncogene 1991;6:765-70.
23. 23. Konishi M, Kikuchi-Yanoshita R, Tanaka K, Salo C, Tsuruta K, Maeda Y, et al. Genetic changes and histopathological grades in human hepatocellular carcinomas. Jpn J Cancer Res 1993;84: 893-9.
24. 24. Ding S-F, Habib NA, Dooley J, Wood C, Bowles L, Delhanty JDA. Loss of constitutional heterozygosity on chromosome 5q in hepatocellular carcinoma without cirrhosis. Br J Cancer 1991; 64:1083-7.
25. 25. De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, Jirtle RL. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 1995;10: 1725-9.
26. 26. Emi M, Fujiwara Y, Nakajima T, Tsuchiya E, Tsuda H, Hirohashi S, et al. Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer. Cancer Res 1992;52:5368-76.
27. 27. Emi M, Fujiwara Y, Ohata H, Tsuda H, Hirohashi S, Koike M, et al. Allelic loss at chromosome band 8p21.3-p22 is associated with progression of hepatocellular carcinoma. Genes Chromosomes Cancer 1993;7:152-7.
28. 28. Fujimori M, Tokino T, Hino O, Kitagawa T, Imamura T, Okamoto E, et al. Allelotype study of primary hepatocellular carcinoma. Cancer Res 1991;51:89-93.
29. 29. Takahashi K, Kudo J, Ishibashi H, Hirata Y, Niho Y. Frequent loss of heterozygosity on chromosome 22 in hepatocellular carcinoma. Hepatology 1992;17:794-9.
30. 30. Wang HP, Rogler CE. Deletions in human chromosome arms 11p and 13q in primary hepatocellular carcinomas. Cytogenet Cell Genet 1988;48:72-8.
31. 31. Walker GJ, Hayward NK, Falvey S, Cooksley WGE. Loss of somatic heterozygosity in hepatocellular carcinoma. Cancer Res 1991;51:4367-70.
32. 32. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JPJ, Davidson NE, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55:4525-30.
33. 33. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994;91: 9700-4.
34. 34. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 1995,92:7416-9.
35. 35. Makos M, Nelkin BD, Lerman MI, Latif F, Zbar B, Baylin SB. Distinct hypermethylation patterns occur at altered chromosome loci in human lung and colon cancer. Proc Natl Acad Sci USA 1992;89:1929-33.
36. 36. Buchagen DL, Qiu L, Etkind P. Homozygous deletion, rearrangement and hypermethylation implicate chromosome region 3p14.3-3p21.3 in sporadic breast-cancer development. Int J Cancer 1994;57:473-9.
37. 37. Cheah MSC, Wallace CD, Huffman RM. Hypomethylation of DNA in human cancer cells: a site-specific change in the c-myc oncogene. J Natl Cancer Inst 1984;73:1057-65.
38. 38. Vachtenheim J, Horakowa I, Novotna H. Hypomethylation of CCGG sites in the 3′ region of H-ras protooncogene is frequent and is associated with H-Ras allele loss in non-small cell lung cancer. Cancer Res 1994;54:1145-8.
39. 39. Cedar H, Razin A. DNA methylation and development. Biochem Biophys Acta 1990;1049:1-8.
40. 40. El-Deiry WS, Nelkin BD, Celano P, Yen R-W, Falco JP, Hamilton SR, et al. High expression of the DNA methyltransferase gene characterises human neoplastie cells and progression stages of colon cancer. Proc Natl Acad Sci USA 1991;88: 3470-4.
41. 41. Issa J-P, Vertino PM, Wu J, Sazawal S, Celano P, Nelkin BD, et al. Increased cytosine DNA-methyltransferase activity during colon cancer progression. J Natl Cancer Inst 1993;85:1235-40.
42. 42. Wu J, Issa J-P, Herman J, Bassett DE, Nelkin BD, Baylin SB. Expression of an exogenous cukaryotie DNA methytransferase gene induces transformation of NIH 3T3 tells. Proc Natl Acad Sci USA 1993;90:8891-5.
43. 43. MacLeod AR, Szyf M. Expression of antisense to DNA methytransferase mRNA induces DNA methylation and inhibits tumorigenesis. J Biol Chem 1995;270:8037-43.
44. 44. Ramchandani S, MacLeod AR, Pinard M, von Hofe E, Szyf M. Inhibition of tumorigenesis by a cytosine DNA, methyltransferase, antisense oligodeoxynucleotide. Proc Natl Acad Sci USA 1997;94:684-9.
45. 45. Laid PW, Laune J-G, Fazeli A, Dickinson SL, Jung WE, Li E, et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995;81:197-205.
46. 46. Sun L, Hui A-M, Kanai Y, Sakamoto M, Hirohashi S. Increased DNA methyltransferase expression is associated with an early stage of human hepatocarcinogenesis. Jpn J Cancer Res 1998; 88:1165-70.
47. 47. Sasaki T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP. Allele-specific hypermethylation of the retinoblastoma tumor-suppression gene. Am J Hum Genet 1991;48:880-8.
48. 48. Wales MM, Bile MA, El Deiry W, Nelkin BD, Issa J-P, Cavenee WK, et al. p53 activates expression of HIC-1, a new candidate tumor suppressor gene on 17p13.3. Nat Med 1995;1:570-7.
49. 49. Kanai Y, Hui A-M, Sun L, Ushijima S, Sakamoto M, Tsuda H, et al. DNA hypermethylation at the D17S5 locus and reduced HIC-1 mRNA expression are associated with hepatocarcinogenesis. Hepatology 1999;29:703-9.
50. 50. Makos M, Nelkin B, Reiter RE, Gnarra JR, Brooks J, Issacs W, et al. Regional DNA hypermethylation at D17S5 precedes 17p structural changes in the progression of renal tumors. Cancer Res 1993;53:2719-22.
51. 51. Pieretti M, Powell DE, Gallion HH, Conway PS, Case EA, Turker MS. Hypermethylation at a chromosome 17 'hot spot' is a common event in ovarian cancer. Hum Pathol 1995;26:398-401.
52. 52. Kanai Y, Ushijima S, Tsuda H, Sakamoto M, Sugimura T, Hirohashi S. Aberrant DNA methylation on chromosome 16 is an early event in hepatocarcinogenesis. Jpn J Cancer Res 1996; 87:1210-7.
53. 53. Yang AS, Shen J-C, Zingg J-M, Mi S, Jones PA. Hha I and Hpa II DNA methyltransferase bind DNA mismatches, methylate uracil and block DNA repair. Nucleic Acids Res 1995;23: 1380-7.
54. 54. Shen J-C, Rideout III WM, Jones PA. High frequency mutagenesis by a DNA methyltransferase. Cell 1992;71:1073-80.
55. 55. Hunter T, Pines J. Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age. Cell 1994;79:573-82.
56. 56. Peter M, Herskowitz I. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 1994;79: 181-4.
57. 57. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 1995;11:210-2.
58. 58. Hussussian CJ, Ptruewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15-21.
59. 59. Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y. Frequent somatic mutation of the MTS1/CDK41 (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 1994;54:3396-7.
60. INK4 in hepatocellular carcinoma. Hepatology 1996;24:575-9.
61. WAF1/CIP1 expression and p53 mutation in hepatocellular carcinomas. Hepatology 1997;25:575-9.
62. Kip1 expression in hepatocellular carcinomas. Cancer Lett 1998;132:67-73.
63. 63. Nishida N, Fukuda Y, Komeda T, Kita R, Sando T, Pukukawa M, et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res 1994;54:3107-10.
64. 64. Hui A-M, Sakamoto M, Kanai Y, Ino Y, Gotoh M, Hirohashi S. Cyclin-dependent kinase inhibitors and hepatocarcinogenesis. In: Tahara E, Sugimachi K, Oohara T, editors. Recent advances in gastroenterological carcinogenesis. Bologna: Monduzzi Editore; 1996. p. 481-5.
65. 65. Hui A-M, Makuuchi M, Li X. Cell cycle regulators and human hepatocarcinogencsis. Hepatogastroenterology 1998;45:1635-42.